Pulmonx公司在2025年的Q4收入略有下降,原因是美国销售问题和中国的核准延迟,但获得了资金,预计2026年的业绩会有所改善。 Pulmonx saw slight revenue decline in Q4 2025 due to U.S. sales issues and delayed China approvals, but secured funding and projected improved performance for 2026.

Pulmonx报告,2025年第4季度收入为2 260万美元,比上一年下降5%,全年收入为9 050万美元,每年增长8%。 Pulmonx reported Q4 2025 revenue of $22.6 million, a 5% drop year-over-year, with full-year revenue at $90.5 million, up 8% annually. 美国的销售量由于国内销售力问题而下降,而国际增长因中国的核准延迟而受阻,预计2026年底将恢复。 U.S. sales declined due to internal sales force issues, while international growth was hindered by delayed China approvals, expected to resume in late 2026. 该公司获得了一个6 000万美元的五年信贷机制,到期日延长至2031年,其中包括基于里程碑的高达2 000万美元的资金。 The company secured a $60 million five-year credit facility with maturity extended to 2031, including up to $20 million in milestone-based funding. 降低成本和改善总利润率(问题4中为78%)证明净损失较小。 Cost reductions and improved gross margins—78% in Q4—supported a narrower net loss. Pulmonx(Pulmonx)预测2026年的收入为90万-92亿美元,其中美国高位数的增长率为Q4,现金流改善,年现金燃烧率降低近30%。 Pulmonx projects 2026 revenue of $90M–$92M, with high-single-digit U.S. growth by Q4 and improved cash flow, aiming for nearly 30% lower annual cash burn.